Results 161 to 170 of about 288,435 (354)

Assessment of Quality of Life in Patients with Advanced Melanoma Receiving Immunotherapy with Checkpoint Inhibitors

, 2023
A. S. Sarmatova, R. V. Orlova, Natalia V. Zhukova, С. И. Кутукова, N. P. Belyak   +4 more
openalex   +1 more source

T Cell Glycoengineering to Modulate Immune‐Tumor Crosstalk: A Universal Non‐Genetic Strategy for Enhanced Tumor Immunotherapy

Advanced Science, EarlyView.
This study describes a T cell surface engineering strategy that integrates polymer materials with tumor immunology, aiming to achieve broad‐spectrum anti‐tumor applications of glycopolymer‐engineered T (G‐T) cells via non‐genetic modification. Glycopolymer engineering generally modulates immune‐tumor crosstalk through specific cell‐cell interactions ...
Lihua Yao, He Yang, Fangjian Shan, Xiaomeng Niu, Yichen Wang, Hengyuan Zhang, Sujian Wang, Gaojian Chen, Hong Chen   +8 more
wiley   +1 more source

Uveal melanoma: Recent advances in immunotherapy

World Journal of Clinical Oncology
Uveal melanoma (UM) is the most common primary intraocular cancer in adults. The incidence in Europe and the United States is 6-7 per million population per year. Although most primary UMs can be successfully treated and locally controlled by irradiation therapy or local tumor resection, up to 50% of UM patients develop metastases that usually involve ...
Sorrentino, Francesco Saverio, De Rosa, Francesco, Di Terlizzi, Patrick, Toneatto, Giacomo, Gabai, Andrea, Finocchio, Lucia, Salati, Carlo, Spadea, Leopoldo, Zeppieri, Marco   +8 more
openaire   +2 more sources

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers [PDF]

, 2004
J. Blake Bartlett, A Michael, Ian Clarke, Keith Dredge, Steve Nicholson, Hartmut Kristeleit, A. Polychronis, H. Pandha, George W. Muller, David Stirling, Jerome B. Zeldis, Angus Dalgleish   +11 more
openalex   +1 more source

Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways [PDF]

, 2023
Saber İmani, Wenqiong Ma, Zexiu Wu, Mazaher Maghsoudloo, Iqra Ijaz, Marzieh Dehghan Shasaltaneh, Yuqin Zhang, Qiao Weng, Junjiang Fu, Qinglian Wen   +9 more
openalex   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Malignant Melanoma of Nose and Paranasal Sinuses: 2 Case Reports [PDF]

, 2010
Malignant melanoma is one of the rare and highly aggressive diseases of the sinonasal cavity. High index of suspicion is required for diagnosis as the patient usually presents with non specific signs and symptoms.
Bhagat, S, Bist, SS, Gupta, N, Singh, R, Varshney, S   +4 more
core   +1 more source

Supplementary Data 1 from Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial

, 2023
Espen B. Ellingsen, Steven O’Day, Artur Mezheyeuski, Agnieszka Gromadka, Trevor Clancy, Timothy S. Kristedja, Mohammed Milhem, Yousef Zakharia   +7 more
openalex   +1 more source

Immune Predictors of Radiotherapy Outcomes in Cervical Cancer

Advanced Science, EarlyView.
This study reveals dynamic immune remodeling in cervical cancer following radiotherapy. Single‐cell analysis identifies the C3/C3AR1 axis as a central mediator of epithelial–myeloid crosstalk, whose inhibition reduces treatment efficacy in mice. Guided by these insights, the eight‐feature machine‐learning model: Cervical Cancer Radiotherapy Immune ...
Linghao Wang, Jie Zhu, Zequn Ding, Zhiyuan Xie, Xingchen Liu, Feihong Zhang, Xiaojun Liu, Yan Zhang, Haiyan Chen   +8 more
wiley   +1 more source